Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial
Date
2024
Authors
Loo, S.
Iland, H.
Tiong, I.S.
Westerman, D.
Othman, J.
Marlton, P.
Chua, C.C.
Purtill, D.
Rose, H.
Fleming, S.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Conference item
Citation
Abstracts of the 66th Annual Meeting of the American Society of Hematology (ASH 2024), as published in Blood, 2024, vol.144, iss.Suppl. 1, pp.223-225
Statement of Responsibility
Sun Loo, Harry Iland, Ing Soo Tiong, David Westerman, Jad Othman, Paula Marlton, Chong Chyn Chua, Duncan Purtill, Hannah Rose, Shaun Fleming, Deepak Singhal, Anoop K Enjeti, William S. Stevenson, Teng Fong Ng, McCulloch Derek, Lachlin Vaughan, Robin Gasiorowski, Adam Ivey, Amanda Souza, Revati Pattani, Natasha S. Anstee, Rachel Koldej, David S. Ritchie, Sanam Loghavi, Naval Daver, Courtney D. DiNardo, Andrew W. Roberts, Carolyn S. Grove, M, John Reynolds, Andrew H Wei
Conference Name
66th Annual Meeting of the American Society of Hematology (ASH) (7 Dec 2024 - 10 Dec 2024 : San Diego, CA, and online)
Abstract
Abstract not available
School/Discipline
Dissertation Note
Provenance
Description
Oral Abstract: 619.Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment
Access Status
Rights
© 2024 American Society of Hematology. Published by Elsevier Inc. All rights reserved.